Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CAMILO JIMENEZ and MOUHAMMED A HABRA.
CAMILO JIMENEZ
Connection Strength
5.809
MOUHAMMED A HABRA
  1. Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? Cancers (Basel). 2022 Jan 18; 14(3).
    View in: PubMed
    Score: 0.815
  2. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist. 2024 Jul 05; 29(7):575-580.
    View in: PubMed
    Score: 0.242
  3. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
    View in: PubMed
    Score: 0.238
  4. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):658-667.
    View in: PubMed
    Score: 0.238
  5. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):649-657.
    View in: PubMed
    Score: 0.238
  6. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.
    View in: PubMed
    Score: 0.230
  7. TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
    View in: PubMed
    Score: 0.222
  8. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
    View in: PubMed
    Score: 0.207
  9. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8).
    View in: PubMed
    Score: 0.185
  10. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab. 2020 05 01; 105(5).
    View in: PubMed
    Score: 0.181
  11. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.179
  12. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
    View in: PubMed
    Score: 0.173
  13. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2020 04 01; 146(7):1836-1840.
    View in: PubMed
    Score: 0.171
  14. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015 Oct 01; 75(19):4131-42.
    View in: PubMed
    Score: 0.131
  15. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
    View in: PubMed
    Score: 0.130
  16. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors: a case series with comparative analysis. Endocr Pract. 2014 Sep; 20(9):864-9.
    View in: PubMed
    Score: 0.122
  17. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014 Sep; 171(3):R111-22.
    View in: PubMed
    Score: 0.120
  18. Mitotane-induced hyperlipidemia: a retrospective cohort study. Int J Endocrinol. 2013; 2013:624962.
    View in: PubMed
    Score: 0.116
  19. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899.
    View in: PubMed
    Score: 0.115
  20. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf). 2014 Mar; 80(3):342-7.
    View in: PubMed
    Score: 0.114
  21. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
    View in: PubMed
    Score: 0.114
  22. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013 Aug; 15(4):356-71.
    View in: PubMed
    Score: 0.113
  23. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013 Apr; 98(4):1492-7.
    View in: PubMed
    Score: 0.110
  24. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Jan; 98(1):192-7.
    View in: PubMed
    Score: 0.108
  25. [?8F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol. 2012 Sep 10; 30(26):e246-9.
    View in: PubMed
    Score: 0.104
  26. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012 Jun 01; 118(11):2804-12.
    View in: PubMed
    Score: 0.100
  27. Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication. J Clin Oncol. 2011 Jun 01; 29(16):e462-4.
    View in: PubMed
    Score: 0.096
  28. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
    View in: PubMed
    Score: 0.096
  29. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25.
    View in: PubMed
    Score: 0.095
  30. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011 Feb; 21(2):189-92.
    View in: PubMed
    Score: 0.095
  31. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine. 2010 Feb; 37(1):209-12.
    View in: PubMed
    Score: 0.088
  32. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract. 2008 Dec; 14(9):1108-14.
    View in: PubMed
    Score: 0.082
  33. SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
    View in: PubMed
    Score: 0.062
  34. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004 Aug; 89(8):4142-5.
    View in: PubMed
    Score: 0.061
  35. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. Eur J Cancer. 2024 Sep; 208:114122.
    View in: PubMed
    Score: 0.060
  36. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery. 2022 08; 172(2):559-566.
    View in: PubMed
    Score: 0.052
  37. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
    View in: PubMed
    Score: 0.045
  38. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.035
  39. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
    View in: PubMed
    Score: 0.030
  40. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.030
  41. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
    View in: PubMed
    Score: 0.027
  42. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov; 97(11):4040-50.
    View in: PubMed
    Score: 0.027
  43. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.